TuHURA Biosciences, Inc.
HURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -19.37% | -286.86% | -2,365.77% | -925.35% |
| EV / EBITDA | -3.67 | -0.10 | 1.44 | 0.70 |
| Quality | ||||
| ROIC | -119.28% | -3,785.74% | -79.84% | 6,992.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.41 | 0.80 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -22.91% | -59.45% | -14.89% | 65.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.05 | 1.48 | 0.82 |
| Interest Coverage | -4.26 | -1,592.72 | 0.00 | -11.53 |
| Efficiency | ||||
| Inventory Turnover | 0.54 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,188.70 | 0.00 | 0.00 | 0.00 |